Glycan therapeutic compositions and related methods thereof
Inventors
VON MALTZAHN, GEOFFREY A. • Yamanaka, Yvonne J. • Silverman, Jared • Milwid, John Miles • Rubens, Jacob Rosenblum • GEREMIA, John M.
Assignees
Interested in licensing this patent?
MTEC can help explore whether this patent might be available for licensing for your application.
Publication Number
US-11883422-B2
Publication Date
2024-01-30
Expiration Date
Abstract
Preparations of glycan therapeutics, pharmaceutical compositions, dietary supplements and medical foods thereof are provided, and methods of using said glycan therapeutics, e.g. in cancer therapy.
Core Innovation
The invention relates to glycan therapeutic preparations administered to a subject to reduce inflammation of a gastrointestinal inflammatory disease in a subject having an immune imbalance. The glycan therapeutic preparation comprises branched glycans having glucose, galactose, arabinose, mannose, fructose, xylose, fucose, or rhamnose glycan units, and is characterized by an average degree of branching (DB) of at least 0.01.
The preparation further comprises glycans in which at least 50% have a degree of polymerization (DP) of at least 3 and less than 30 glycan units. The ratio of alpha- to beta-glycosidic bonds present in the glycans is between about 1:1 to about 5:1.
The disclosed compositions are presented as glycan therapeutic preparations and are linked to reduction of gastrointestinal inflammation in subjects with immune imbalance. The partial content also describes formulation embodiments such as pharmaceutical compositions, medical foods, and dietary supplements, together with characterization and quality metrics associated with glycan structure and composition.
Claims Coverage
The provided content recites one independent method claim directed to reducing inflammation in a gastrointestinal inflammatory disease by administering a glycan therapeutic preparation. The inventive features number four and jointly define the glycan population and bond characteristics used for the reduction of inflammation.
Branched glycan composition with specified monosaccharide units
The glycan therapeutic preparation comprises branched glycans comprising glucose, galactose, arabinose, mannose, fructose, xylose, fucose, or rhamnose glycan units.
Minimum average degree of branching
The glycan therapeutic preparation comprises an average degree of branching (DB) of at least 0.01.
Constrained degree of polymerization population
At least 50% of the glycans in the glycan therapeutic preparation have a degree of polymerization (DP) of at least 3 and less than 30 glycan units.
Alpha-to-beta glycosidic bond ratio window
The ratio of alpha- to beta-glycosidic bonds present in the glycans of the glycan therapeutic preparation is between about 1:1 to about 5:1, thereby reducing inflammation of the gastrointestinal inflammatory disease in the subject having the immune imbalance.
Overall, the claim coverage centers on administering a glycan therapeutic preparation with branched glycans defined by particular monosaccharide units, an average DB of at least 0.01, a DP distribution where at least 50% of glycans fall within DP at least 3 and less than 30, and an alpha:beta glycosidic bond ratio between about 1:1 and about 5:1 to reduce gastrointestinal inflammation in a subject with immune imbalance.
Stated Advantages
Reducing inflammation of the gastrointestinal inflammatory disease in the subject having the immune imbalance.
Documented Applications
A method for reducing inflammation of a gastrointestinal inflammatory disease in a subject having an immune imbalance by administering an effective amount of a glycan therapeutic preparation.
Modulating intestinal microbiota taxa and associated SCFAs and bile acids in the context of the described therapeutic effects.
Cancer-related use cases are referenced in the document as integration with cancer therapies such as checkpoint inhibitors, chemotherapy, and radiation.
Formulation embodiments such as pharmaceutical compositions, medical foods, and dietary supplements.
Interested in licensing this patent?